Congratulations to our own Andy Geall, CDO and Co-founder, on his induction as a Fellow to the AIMBE in recognition for outstanding contributions to and leadership in the field of nucleic acid delivery and the development of mRNA vaccine.

Replicate is at the World Vaccine Congress in the capitol! Check out CMO Zelanna Goldberg’s presentation "Outstanding Clinical Performance from a Next Generation srRNA vaccine" today at 12 pm ET. We hope to see you there! #WVCDC #RNA

Join Andy Geall onsite at #TIDESUSA, where he is moderating a panel highlighting the next chapter of mRNA-based medicines and the broad utility of the field in addressing current hurdles in infectious disease and other therapeutic areas.

Come see us in San Diego for the #RNALeaders USA Congress! Today, our CEO Nathaniel Wang will discuss scaling strategies for #RNAtherapies during a keynote panel before presenting on key improvements enabled by our #srRNA technology in the afternoon. #mRNA #RNA #vaccine

Join our CEO Nathaniel Wang and CBO Rachael Lester for a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6th. We look forward to engaging discussions and collaborations that shape the future of #RNATherapies! #RNA #srRNA #mRNA #vaccine

San Diego is a true hub of scientific innovation and a premier location for #RNATherapeutics R&D! Connect 3rd Annual Innovation Day, our CDO and Co-founder Andrew Geall will showcase the positive impact of #RNA medicines on public health. #srRNA #Biotech #SanDiego #IDSD24

Our CBO Rachael Lester will be in NYC next week to present at the Oppenheimer Private Healthcare Company Showcase. Reach out to schedule meetings and learn how we’re expanding the utility of #RNAtherapeutics with our next generation #srRNA vectors. #biotech #mRNA #vaccine

Next week, Replicate will attend the DCVMN International 25th Annual General Meeting. We look forward to insightful discussions on prioritizing accessibility in #vaccine development, manufacturing, and roll out to ensure that scientific advancements benefit all populations. #RNA

Mark your calendar: Next week, our Head of Research & Development, Parinaz (Paris) Aliahmad, will present clinical data demonstrating the expanded therapeutic index of a novel #srRNA #vaccine at the 12th International #mRNA Health Conference. We hope to see you there!

On November 14th, our CBO Rachael Lester will participate in a roundtable hosted by Financial Times focused on funding biopharma innovation to discuss asset development and corporate growth in a complex and evolving macroeconomic environment. #Biotech #BusinessDevelopment #Industry

Don’t miss our presentation today at the 12th International #mRNA Health Conference. Our Head of R&D, Parinaz (Paris) Aliahmad, will share data from our rabies clinical trial showing the expanded therapeutic index of a novel, optimized #srRNA #vaccine. #Biotech #RNA

Replicate CEO Nathaniel Wang and CBO Rachael Lester will be at the Piper Sandler 36th Annual Healthcare Conference held December 3-5 in NYC. Reach out to schedule 1:1s and hear more about our latest company updates - we hope to see you there! #srRNA #biotech #mRNA #RNA #vaccine

Today we announced a paper in Nature Communications highlighting our Phase I clinical study of RBI-4000 an #srRNA rabies #vaccine. Results suggest RBI-4000 could offer much needed treatment option for #rabies. Congratulations to all who contributed to this work! nature.com/articles/s4146…

Big news today: Replicate enters a $550M+ exclusive deal with Novo Nordisk Together, we’ll advance our self-replicating RNA (srRNA) technology for obesity, type 2 diabetes, and cardiometabolic disease. A milestone moment for RNA therapeutics. Read more: replicatebioscience.com/replicate-bios…

We’re kicking off September at #RNALeaders USA Congress – where CEO Nathaniel Wang will speak to the advantages of srRNA, including durability. We look forward to discussing Replicate’s latest progress, as well as the advantages of srRNA - we hope to see you there!

Today we announced the publication of our Phase 1 trial for RBI-4000, our #srRNA rabies vaccine, in Communications Medicine. Results show durability 6x greater than standard vaccines - a first for #RNA. Learn more: nature.com/articles/s4385…